Table 3.

Cox regression factors affecting OS/DFS/relapse in patients with MC.

N = 106 patients	OS(UV/MV)			DFS(UV/MV)			Relapse (UV/MV)
	HR (UV/MV)	CI (UV/MV)	P (UV/MV)	HR (UV/MV)	CI UV/MV)	P (UV/MV)	HR (UV/MV)	CI (UV/MV)	P (UV/MV)
Conditioning regimen (ref RIC)	0.93	0.7–1.2	0.66	1.01	0.7–1.2	0.88	0.95	0.6–1.3	0.78
Disease risk (DRI, ref high risk)	1.1	0.5–2.3	0.65	1.17	0.6–2.2	0.61	1.12	0.5–2.4	0.76
Age (ref > 52)	1.34	0.7–2.3	0.34	1.12	0.5–1.9	0.58	1.11	0.6–2.1	0.73
Presence of cGVHD (ref yes)	1.08	0.5–2.0	0.79	0.83	0.4–1.4	0.53	0.76	0.3–1.5	0.45
Matching (ref 9/10)	0.64	0.3–1.2	0.17	0.75	0.4–1.3	0.31	0.73	0.3–1.5	0.39
CD 3 day 60 (ref < 50)	1.24	0.6–2.2	0.55	1.23	0.6–2.1	0.49	0.90	0.4–1.8	0.78
Response to pDLI (No response vs response)	5.95/5.9	2.3–15/2.3–15	0.001/ 0.001	5.45/5.4	2.4–12/2.4–12	0.0001/ 0.0001	9.45/9.4	2.8–30/2.8–30	0.0001/ 0.0001
Presence of severe cGVHD (ref yes)	1.42	0.6–3.5	0.37	1.09	0.4–2.5	0.82	0.78	0.2–2.5	0.68

OS overall survival, DFS disease-free survival, GVHD graft vs host disease, BM bone marrow, NRM non-relapse mortality, MA myeloablative regimen, RIC reduced-intensity conditioning, MC mixed chimerism, pDLI pre-emptive donor lymphocyte infusion.